The aims of her lab are to understand the drivers and predictors of prognosis in breast cancer using high-throughput genomic technologies as well as using in vitro and in vivo preclinical models. Ultimately, the aim of her lab is to translate such findings into therapeutic approaches for breast cancer patients. Recently, she has developed a keen interest in immunotherapeutic approaches, as she was first to report on the positive prognostic value of tumor infiltrating lymphocytes in triple negative and HER2-positive breast cancer. Further preclinical work has supported the concept that immune approaches could be beneficial in these breast cancer subtypes. She also plays a role in many breast cancer clinical trials that evaluate targeted approaches as well as immunotherapies.